+ 2.69
+ 1.88%

3 Short Squeeze Candidates In The Health Care Sector

May 6, 2021 2:11 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
3 Short Squeeze Candidates In The Health Care Sector

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

A stock's float is the number of shares that trade freely on the public market. Because insiders and institutional investors don’t typically trade their shares on a daily basis, those shares don’t typically contribute to a stock's near-term liquidity.

Float is the number of shares that remain after accounting for insider and institutional ownership.

Why Is It Important? When a stock gains positive momentum in the market, momentum buyers can rush in all at once. If a stock has a high short interest, short covering can quickly ramp up demand for shares, triggering a short squeeze. Since low float stocks have relatively few shares trading freely, a major imbalance in supply and demand can serve as rocket fuel for the share price.

Buying a low float stock with high short interest isn’t a guarantee of a short squeeze. There still typically needs to be some form of catalyst to get the stock moving in the first place. However, traders can keep an eye on these stocks for any signs of life to try to catch most of a potential big move.

Related Link: 3 Short Squeeze Candidates In The Consumer Staples Sector

Short Squeeze Candidates: Here are three healthcare sector stocks that have all the ingredients for a short squeeze.

Prometheus Biosciences Inc (NASDAQ:RXDX)
Prometheus Biosciences is a biotechnology company focused on therapies and diagnostic products for the treatment of inflammatory bowel disease (IBD). The stock completed its IPO in March and is also the perfect short squeeze candidate within the sector.

Prometheus’ 970,000-share float is minuscule, creating plenty of opportunity for extreme volatility if trading volume rises. Prometheus also has 30.2% of its float held short, a fairly high short percent of float.

Finally, the stock has already demonstrated its potential for extreme volatility. In about two months on the market, Prometheus shares have already swung from its IPO price of $19 all the way up to $28.33 in March, back down to $16.11 a couple of weeks later, back up to $30.62 in mid-April and then back down to $21.84 on Thursday.

Vyant Bio is a company that was formed by the merger of Cancer Genetics and StemoniX in late March.

Cancer Genetics reported an $8.6 million net loss on just $867,000 in revenue in 2020, but as many meme stock traders have realized in 2021, short squeezes are technical market phenomena and don’t necessarily have anything to do with the company’s underlying business fundamentals or the stock’s long-term outlook.

Vyant has a one-two punch of a small float of 2.6 million shares and a high short percent of float of 30.1%. In addition, short squeeze traders have frequently targeted stocks trading under $5 per share this year, and Vyant’s shares currently trade at just $3.18.

Thermogenesis Holdings Inc (NASDAQ:THMO)

Thermogenesis is a biotech company that specializes in cell processing technologies for cell and gene therapy.

Thermogenesis’ 26.4% short percent of float and its 4.8 million-share float provide plenty of opportunity for a potential squeeze. The stock also has a history of extreme volatility. In the first six weeks of 2021, Thermogenesis’ stock price surged from under $2 to as high as $4.45.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

3 Small Cap Stocks That Are Short Squeeze Candidates

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. read more

6 Biotech Stocks Jefferies Says Are Undervalued

Ignyta Gets A Bullish Initiation From JPMorgan

Ignyta's Entrectinib Data May Come By Year's End; Cantor Keeps Buy Rating, But Stock Slips 4%